Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Options -- Ignore unavailable to you. Want to Upgrade?

To: Teflon who wrote (4324)	3/7/2000 8:58:00 AM
From: Jill	Respond to of 8096

Tef, I'd love to hear what someone like Steve Mamus thinks about this. Steve, you lurqing? He's an oncologist. From my perspective, it's exciting, I just can't tell how close to fruition it is. I find it exciting because angiogenesis, or formation of new blood vessels, is how tumors manage to grow and spread. When Entremed skyrocketed a long time ago on a NY Times article by Gina Kolata, it was because of experiments in mice with anti-angiogenesis drugs. This technology is different, but once again it targets tumors via their vascular system, and that could have huge consequences. It seems to me that you could shrink tumors before operating; could also keep them in some kind of stasis. This is speculation on my part tho, and I'd love to hear some medical input from our thread. Jill